Sellas Life Sciences Group, Inc. (SLS) — 10-Q Filings
All 10-Q filings from Sellas Life Sciences Group, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
SELLAS Narrows Losses, Boosts Cash Reserves with $50M+ in Financing
— Nov 12, 2025 Risk: medium
SELLAS Life Sciences Group, Inc. reported a net loss of $6.791 million for the three months ended September 30, 2025, an improvement from a net loss of $7.108 m -
SELLAS Reports No Revenue, Bolsters Capital with January Offering
— Aug 12, 2025 Risk: high
SELLAS Life Sciences Group, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net -
SELLAS Life Sciences Group Files Q1 2025 10-Q
— May 13, 2025 Risk: low
SELLAS Life Sciences Group, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as Galena Biopharma, Inc. and RXi -
SELLAS Life Sciences Group 10-Q Filing
— Nov 13, 2024 Risk: medium
SELLAS Life Sciences Group, Inc. filed a 10-Q for the period ending September 30, 2024. The company, formerly known as Galena Biopharma, Inc. and RXi Pharmaceut -
SELLAS Life Sciences Group Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
SELLAS Life Sciences Group, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its busi -
SELLAS Life Sciences Group, Inc. Files 10-Q for Period Ending March 31, 2024
— May 14, 2024 Risk: low
SELLAS Life Sciences Group, Inc. (SLS) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. The filing is a 10-Q report for SELLAS Life Sciences Group,
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX